Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.68 |
| ▸ | ALPL | P05186 | 2/20 | 0.52 |
| ▸ | ALPI | P09923 | 2/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532152 | 0.89 | PIK3CA (0.73) | PIK3CAMKNK1MKNK2 | |
| SCHEMBL15975838 | 0.88 | PIK3CA (0.55) | PIK3CAALPLALPIMKNK1MKNK2 | |
| SCHEMBL532239 | 0.83 | ALPL (0.48) | PIK3CAALPLALPI | |
| SCHEMBL533327 | 0.82 | PIK3CA (0.70) | PIK3CA | |
| SCHEMBL2121693 | 0.82 | PIK3CA (0.70) | PIK3CA | |
| SCHEMBL533158 | 0.82 | PIK3CA (0.81) | PIK3CA | |
| SCHEMBL533617 | 0.82 | PIK3CA (0.76) | PIK3CA | |
| SCHEMBL533128 | 0.81 | PIK3CA (1.00) | PIK3CAALPLALPI | |
| SCHEMBL2616022 | 0.80 | PIK3CA (0.44) | PIK3CAALPLALPIPIM1EGLN2 | |
| SCHEMBL532103 | 0.79 | PIK3CA (0.76) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| CN-102388055-A | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO | 2012-03-21 | — | — | CN | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | PIK3CA 1/4885ALPL 3588/4885ALPI 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.